NASDAQ:INM InMed Pharmaceuticals (INM) Stock Price, News & Analysis $2.22 +0.04 (+1.83%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.16 -0.06 (-2.70%) As of 08/29/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About InMed Pharmaceuticals Stock (NASDAQ:INM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InMed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.17▼$2.2350-Day Range$2.18▼$3.8752-Week Range$1.72▼$8.27Volume24,839 shsAverage Volume49,591 shsMarket Capitalization$4.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada. Read More InMed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreINM MarketRank™: InMed Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for InMed Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of InMed Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InMed Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInMed Pharmaceuticals has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about InMed Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.19% of the float of InMed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently decreased by 69.12%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInMed Pharmaceuticals does not currently pay a dividend.Dividend GrowthInMed Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.19% of the float of InMed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently decreased by 69.12%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentInMed Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for InMed Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.43% of the stock of InMed Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 20.12% of the stock of InMed Pharmaceuticals is held by institutions.Read more about InMed Pharmaceuticals' insider trading history. Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INM Stock News HeadlinesCannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightAugust 13, 2025 | finance.yahoo.comInMed Pharmaceuticals Secures $5M in Private PlacementJuly 3, 2025 | theglobeandmail.comHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and declared a historic event would send the yellow metal to $3,150. People laughed at him at the time, but he was off by just two days. Now, Sean has a shocking new prediction for gold … and reveals a little-known way to get ahead of this bull market. | Weiss Ratings (Ad)InMed stock soars after promising Alzheimer’s drug preclinical resultsJune 24, 2025 | in.investing.comInMed Shares Jump After Positive Preclinical Data for INM-901June 24, 2025 | marketwatch.comInMed Pharmaceuticals: InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes ...June 14, 2025 | finanznachrichten.deInMed Pharmaceuticals Board Reshuffle After Director ResignationFebruary 14, 2025 | tipranks.comInMed Pharmaceuticals Second Quarter 2025 Earnings: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024)February 14, 2025 | finance.yahoo.comSee More Headlines INM Stock Analysis - Frequently Asked Questions How have INM shares performed this year? InMed Pharmaceuticals' stock was trading at $4.74 on January 1st, 2025. Since then, INM shares have decreased by 53.2% and is now trading at $2.22. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) posted its earnings results on Monday, May, 12th. The company reported ($1.94) EPS for the quarter. The firm had revenue of $1.26 million for the quarter. InMed Pharmaceuticals had a negative trailing twelve-month return on equity of 107.93% and a negative net margin of 168.87%. When did InMed Pharmaceuticals' stock split? InMed Pharmaceuticals's stock reverse split before market open on Wednesday, September 7th 2022.The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Tesla (TSLA) and PayPal (PYPL). Company Calendar Last Earnings5/12/2025Today8/30/2025Next Earnings (Estimated)9/26/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INM CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)($12.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.68 million Net Margins-168.87% Pretax Margin-168.71% Return on Equity-107.93% Return on Assets-82.97% Debt Debt-to-Equity Ratio0.06 Current Ratio3.49 Quick Ratio3.04 Sales & Book Value Annual Sales$4.60 million Price / Sales0.97 Cash FlowN/A Price / Cash FlowN/A Book Value$20.64 per share Price / Book0.11Miscellaneous Outstanding Shares2,000,000Free Float1,973,000Market Cap$4.44 million OptionableNot Optionable Beta0.29 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:INM) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.